TY - T1的治疗药物监测和流感oroquinolones for multidrug-resistant tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.04454-2020 VL - 57 IS - 4 SP - 2004454 AU - Srivastava, Shashikant AU - Gumbo, Tawanda Y1 - 2021/04/01 UR - //www.qdcxjkg.com/content/57/4/2004454.abstract N2 - We read the paper by Davies Forsman et al. [1] and could not agree more with their findings. The authors report that in the studied geographical area and clinical population, the dose of levofloxacin and moxifloxacin should be increased to achieve the optimal exposure target in order to effectively treat multidrug-resistant tuberculosis, and suggested therapeutic drug monitoring (TDM) to avert any adverse event [1, 2]. The target drug exposure and dose in the study were selected based on the evidence collected using pharmacokinetic/pharmacodynamic studies in both pre-clinical models and in the clinic [3].Fluoroquinolones at currently prescribed standard dose are suboptimal for treatment of multidrug-resistant tuberculosis. The dose should be increased with therapeutic drug monitoring to determine the drug exposure and to prevent adverse events. https://bit.ly/3nMip2Z ER -